To counteract the increased risk of escape by antigenlow tumor cells—a potential drawback of affinity-tuning strategies—a CLEC12A-CCR was introduced to enhance the elimination of ADGRE2lowCLEC12Amed/high AML cells. The gene discussed is CLEC12A; the disease is neoplasm.